We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer is scrapping its phase 3 trial of rare-disease cardiology candidate PF-07265803 and development of the drug, which the company inherited from Array Biopharma in its $11.4 billion acquisition of the company in 2019. Read More
A U.S. District Court in Illinois has found that Eli Lilly shortchanged Medicaid’s drug rebate program in 26 states and must pay a $61 million penalty for violating federal and state false claims acts. Read More
Amgen announced that it is acquiring ChemoCentryx, a developer of oral therapies to treat autoimmune diseases, inflammatory disorders and cancer, for approximately $3.7 billion. Read More
The companies argued that there was no scientific evidence available at the time of the initial labeling of the drugs to justify including such warnings. Read More
Alnylam Pharmaceuticals announced that a year-long phase 3 trial of its drug patisiran showed that the therapy met both its major objectives in patients with transthyretin-mediated amyloidosis (ATTR) with cardiomyopathy, improving patients’ ability to walk and increasing their quality of life. Read More
A U.S. appeals court panel has said no to resurrecting a 2019 lawsuit alleging that AbbVie broke antitrust laws by using a “patent thicket” to cover its blockbuster monoclonal antibody Humira from copycat drugs coming to market, thus exploiting the patent system. Read More
The combination of Merck’s blockbuster anti-PD-1 therapy Keytruda and Eisai’s Lenvima failed to show superiority to the standard of care of Lenvima alone as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Read More
The FDA has approved Coherus BioSciences’ Cimerli (ranibizumab-eqrn) as the first interchangeable biosimilar for Roche’s retinal disease blockbuster Lucentis across all five of its indications. Read More